



American
Urological
Association

Advancing Urology™



SOCIETY FOR BASIC UROLOGIC RESEARCH, INC.



**SBUR/SUO: The New Landscape of Therapy for Advanced Prostate Cancer
Saturday, May 17, 2014**

7:50 – 8:00 am Introduction and Welcome - David Jarrard, MD and Jill Macoska, PhD

Session 1

Moderators: David Jarrard, MD and Jill Macoska, PhD

- 8:00 – 8:15 am Intracrine Androgen Metabolism: New Targets for Treatment directed against Androgen Receptor Action- James Mohler, MD
- 8:15 – 8:30 am Resistance to Therapy: Approaches in the Clinic – Charles Ryan, MD
- 8:30 – 8:45 am Resistance Mechanisms of Androgen Receptor Splice Variants – Scott Dehm, PhD
- 8:45 – 9:00 am Androgen Receptor N-Terminal Domain Inhibitors for the Treatment of CRPC – Marianne Sadar, PhD
- 9:00 – 9:20 am Questions and Panel Discussion: Moderator – Joel Nelson, MD

Session 2

Moderators: David Jarrard, MD and Jill Macoska, PhD

- 9:20 – 9:35 am Long Noncoding RNA Control of the Androgen Receptor in CRPC – Christopher Evans, MD
- 9:35 – 9:50 am What's New in Immune Therapy – Eugene Kwon, MD
- 9:50 – 10:05 am Clinical and Molecular Predictors of Survival in Men with CRPC – Christopher Logothetis, MD
- 10:05 – 10:20 am Small Cell Carcinoma Markers in CRPC – Angelo De Marzo, MD, PhD
- 10:20 – 10:50 am Questions and Case Discussions: Integration, Sequencing and Cross Resistance of New Systemic Therapies in CRPC – Moderator: Adam Kibel, MD
Panel: Eugene Kwon, MD, Christopher Evans, MD, Christopher Logothetis, MD, Angelo De Marzo, MD, PhD and Charles Ryan, MD
- 10:50 – 11:00 am Break
- 11:00 – 11:30 am **Coffey Lecture – Cancer and Metastasis: What Ecology Can Teach Us**

Kenneth Pienta, MD is a medical oncologist who has spent a career treating CRPC. He was the PI of the Prostate SPORC at Michigan for ~15 years and directed the GU oncology program in the cancer center prior to a recent move to Johns Hopkins, where he now directs Urology Research. Ken has authored or co-authored >300 clinical or basic research papers largely focused on CRPC. His recent research is focused on mobilization of cancer stem cells for increased exposure to chemotherapeutic agents, and the role(s) of tumor-associated macrophages in prostate cancer progression and metastasis. Dr. Pienta is even a former student of Don Coffey.

Re: SBUR/SUO Joint Session

AUA ACCREDITATION INFORMATION

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 3.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The American Urological Association complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Session I: Bladder Cancer Pathobiology and Therapeutic Targeting

Moderators: Mark Day, PhD and Dan Theodorescu, MD, PhD

- 1:30 – 1:35 p.m. Welcome and Introduction
Mark L. Day, PhD Dan Theodorescu, MD, PhD
University of Michigan University of Colorado, Denver
- 1:35 – 1:55 p.m. Critical Role of FOXA1 in Maintenance of Urothelial Differentiation and Bladder Cancer Progression
David J. DeGraff, PhD
Vanderbilt University
- 2:00 – 2:20 p.m. Progranulin Signalling in Bladder Cancer Progression
Andrea Morrione, PhD
Thomas Jefferson University
- 2:25 – 2:50 p.m. Evaluation of the Anti-Tumor Activity of Dacomitinib in Models of Human Bladder Cancer
Mark L. Day, PhD
University of Michigan
- 2:50 – 3:10 p.m. RhoGD12 Suppresses Bladder Cancer Metastasis via Reduction of Inflammation in the Tumor Microenvironment
Dan Theodorescu, MD, PhD
University of Colorado, Denver
- 3:15 – 3:35 p.m. Mining Public Expression Microarray Data in Translational Studies of Bladder Cancer
Jonathan Ewald, PhD
University of Wisconsin, Madison
- 3:35 p.m. Adjourn

AUA Accreditation Information

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Session II: Of Mice and Men: Comparative Measures of Voiding Function in Man and Beast

Moderator: Aria Olumi, MD

- 1:30 – 1:35 p.m. Welcome and Introduction
Aria Olumi, MD
Massachusetts General Hospital, Harvard Medical School
- 1:35 – 1:55 p.m. The Diabetic Bladder in Mice and Men: Pathobiologies and Voiding Dysfunction
Aria Olumi, MD
Massachusetts General Hospital, Harvard Medical School
- 1:55 – 2:15 p.m. Animal Models of Lower Urinary Tract Dysfunction- Opportunities to Connect Clinical Phenotypes, Mechanisms and Alterations in System Biology
Firouz Daneshgari, MD
Case Western Reserve University
- 2:15 – 2:35 p.m. Cystometry in Rodents and Man - A Comparison
Karl-Erik Andersson, PhD
Wake Forrest University
- 2:35 – 2:55 p.m. Measuring Voiding Function in Mice
Mark Zeidel, MD
Beth Israel Deaconess Medical Center, Harvard Medical School
- 2:55 – 3:15 p.m. Urothelial-Mediated Bladder Dysfunction in Mice and Men
Lori Birder, PhD
University of Pittsburgh
- 3:15 – 4:00 p.m. Panel Discussion with Audience Participation
- 4:00 p.m. Adjourn

Breakout Session II is co-sponsored by the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU).

AUA Accreditation Information

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 2.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.